The Beryllium BioBank consists of a Data Coordinating Center and a Core Specimen Laboratory, housed at National Jewish Health in Denver, Colorado.
The Department of Energy, assisted by a group of clinicians and scientists from National Jewish Health, the Hospital of the University of Pennsylvania, East Tennessee Pulmonary Associates, University of California-San Francisco, and University of California- Los Angeles, collected clinical data and specimens for the Beryllium BioBank. The purpose of the repository is to facilitate research by collecting de-identified biological specimens and clinical information from a large number of workers exposed to beryllium. The BioBank does not directly conduct research.
The BioBank is a resource for future researchers to:
- Identify exposure and genetic risk factors that cause beryllium sensitization and disease
- Improve the detection of beryllium sensitization and CBD
- Define new therapeutics to be tested in the treatment of CBD
- Understand the immune and inflammatory mechanisms that cause beryllium sensitization and CBD
- Develop new biological markers of exposure, biological effect, and disease
- Define clinical and physiologic aspects of beryllium sensitization and CBD
This effort is funded by the U.S. Department of Energy.
Questions about the Beryllium BioBank?
Please contact:
Lisa A. Maier, MD, MSPH, FCCP
National Jewish Health
1400 Jackson St., G204
Denver, CO 80206
303-398-1983
Briana Barkes, MPH
BarkesB@NJHealth.org
